Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Neumora Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
640979 100
(CUSIP Number)
Mark McDonnell
ARCH Venture Management, LLC
8755 W. Higgins Road Suite 1025
Chicago, IL 60631
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
November 12, 2024
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Persons who respond
to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB control number.
CUSIP No. 640979 100 |
13D | Page 2 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Fund VII, L.P.
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
WC
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 640979 100 |
13D | Page 3 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Fund VIII Overage, L.P.
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
WC
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 640979 100 |
13D | Page 4 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Fund X, L.P.
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
WC
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 640979 100 |
13D | Page 5 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Fund X Overage, L.P.
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
WC
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 640979 100 |
13D | Page 6 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Fund XII, L.P.
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
WC
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 640979 100 |
13D | Page 7 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Partners VII, L.P.
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 640979 100 |
13D | Page 8 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Partners X, L.P.
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 640979 100 |
13D | Page 9 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Partners X Overage, L.P.
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SH ARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 640979 100 |
13D | Page 10 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Partners XII, L.P.
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
WC
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
PN
|
CUSIP No. 640979 100 |
13D | Page 11 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Partners VII, LLC
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
OO
|
CUSIP No. 640979 100 |
13D | Page 12 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Partners VIII, LLC
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
OO
|
CUSIP No. 640979 100 |
13D | Page 13 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Partners X, LLC
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
OO
|
CUSIP No. 640979 100 |
13D | Page 14 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
ARCH Venture Partners XII, LLC
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
OO
|
CUSIP No. 640979 100 |
13D | Pag e 15 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
Robert Nelsen
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
IN
|
CUSIP No. 640979 100 |
13D | Page 16 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
Keith Crandell
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
31,932,138 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,932,138 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
IN
|
CUSIP No. 640979 100 |
13D | Page 17 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
Clinton Bybee
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
3,708,794 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
3,708,794 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,708,794 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.3%
|
|||
14 |
TYPE OF REPORTING PERSON
IN
|
CUSIP No. 640979 100 |
13D | Page 18 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
Kristina Burow
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
46,973 Shares
| ||
| 8 | SHARED VOTING POWER
31,932,138 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
46,973 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,979,111 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.8%
|
|||
14 |
TYPE OF REPORTING PERSON
IN
|
CUSIP No. 640979 100 |
13D | Page 19 of 32 Pages |
| 1 | NAME OF REPORTING PERSONS
Steven Gillis
|
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY
|
|||
| 4 | SOURCE OF FUNDS
AF
|
|||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐ | ||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 |
SOLE VOTING POWER
0 Shares
| ||
| 8 | SHARED VOTING POWER
29,610,572 Shares
| |||
| 9 | SOLE DISPOSITIVE POWER
0 Shares
| |||
| 10 | SHARED DISPOSITIVE POWER
29,610,572 Shares
|
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
29,610,572 Shares
|
|||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐ | ||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.3%
|
|||
14 |
TYPE OF REPORTING PERSON
IN
|
CUSIP No. 640979 100 |
13D | Page 20 of 32 Pages |
| Item 1. | Security and Issuer. |
This Amendment No. 2 (the “Amendment No. 2”) to the Schedule 13D filed on September 29, 2023 (the “Original 13D”), related to the Common Stock, $0.0001 par value per share (the “Common Stock”), of Neumora Therapeutics, Inc. (the “Issuer”) having its principal executive office at 490 Arsenal Way, Suite 200, Watertown, Massachusetts, 02472.
| Item 2. | IDENTITY AND BACKGROUND. |
| (a) | This statement is being filed by (1) ARCH Venture Fund VII, L.P. (“AVF VII”), (2) ARCH Venture Partners VII, L.P. (“AVP VII”) which is the sole general partner of AVF VII, (3) ARCH Venture Partners VII, LLC (“AVP VII LLC”) which is the sole general partner of AVP VII, (4) ARCH Venture Fund VIII Overage, L.P. (“AVF VIII Overage”), (5) ARCH Venture Partners VIII, LLC (“AVP VIII LLC”) which is the sole general partner of AVF VIII Overage, (6) ARCH Venture Fund X, L.P. (“AVF X”), (7) ARCH Venture Partners X, L.P. (“AVP X LP”) which is the sole general partner of AVF X, (8) ARCH Venture Partners X, LLC (“AVP X LLC”) which is the sole general partner of AVP X LP and AVP X Overage LP (defined below), (9) ARCH Venture Fund X Overage, L.P. (“AVF X Overage”), (10) ARCH Venture Partners X Overage, L.P. (“AVP X Overage LP”), which is the sole general partner of AVF X Overage, (11) ARCH Venture Fund XII, L.P. (“AVF XII”), (12) ARCH Venture Partners XII, L.P. (“AVP XII LP”) which is the sole general partner of AVF XII, (13) ARCH Venture Partners XII, LLC (“AVP XII LLC”) which is the sole general partner of AVF XII, (13) Keith Crandell (“Crandell”), (14) Robert Nelsen (“Nelsen”), (15) Clinton Bybee (“Bybee”, and together with Nelsen and Crandell, referred to individually as a Managing Director or collectively as the “AVP VII Managing Directors”, “AVP VIII Managing Directors” or “Managing Directors”, (16) Kristina Burow (“Burow”), and (17) Steven Gillis (“Gillis”, and together with Nelsen, Crandell and Burow, referred to individually as “Committee Member” or collectively as either the “AVP X Investment Committee Members” or the “AVP XII Investment Committee Members”). Each of the individuals and entities above shall be referred to herein as a “Reporting Person” and collectively as the “Reporting Persons”. |
| (b) | The business address of each of the Reporting Persons is 8755 West Higgins Road, Suite 1025, Chicago, IL, 60631. |
| (c) | The principal business of AVP VII is to act as the general partner of AVF VII, the principal business of AVP VIII LLC is to act as the general partner of AVF VIII Overage, the principal business of AVP X LP is to act as the general partner of AVF X, the principal business of AVP X Overage LP is to act as the general partner of AVF X Overage, and the principal business of AVP XII is to act as the general partner of AVF XII. The principal business of AVP VII LLC is to act as the general partner of AVP VII LP, the principal business of AVP X LLC is to act as the general partner of AVP X LP and AVF X Overage LP, and the principal business of AVP XII LLC is to act as the general partner of AVP XII LP. The principal business of each of the AVP VII Managing Directors and AVP VIII Managing Directors is to act as managing directors of AVP VII LLC and AVP VIII LLC, respectively, and as managing directors or investment committee members of a number of affiliated partnerships with similar businesses. AVP X Investment Committee Members and AVP XII Investment Committee Members act as investment committee members of AVP X LLC and AVP XII LLC, respectively, and as managing directors or investment committee members of a number of affiliated partnerships with similar businesses. |
| (d) | During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding. |
| (e) | During the five years prior to the date hereof, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. |
| (f) | Each of AVF VII, AVP VII, AVF VIII Overage, AVF X, AVP X LP, AVF X Overage, AVP X Overage LP, AVF XII and AVP XII LP, are limited partnerships organized under the laws of the State of Delaware. Each of AVP VII LLC, AVP VIII LLC, AVP X LLC and AVP XII LLC is a limited liability company organized under the laws of the State of Delaware. Each Managing Director and/or Investment Committee Member is a US citizen. |
CUSIP No. 640979 100 |
13D | Page 21 of 32 Pages |
AVF VIII Overage is the record
owner of 2,321,566 shares of Common Stock (“AVF VIII Overage Record Shares”). AVP VIII LLC, as the sole general partner of
AVF VIII Overage, may be deemed to beneficially own the AVF VIII Overage Record Shares. AVF X is the record owner of 12,205,379
shares of Common Stock (“AVF X Record Shares”). AVP X LP, as the sole general partner of AVF X LP, may be deemed to beneficially
own the AVF X Record Shares. AVP X LLC, as the sole general partner of AVP X LP, may be deemed to beneficially own the AVF X Record
Shares. AVF X Overage is the record holder of 11,886,758 shares of Common Stock (“AVF X Overage Record Shares”). AVP X Overage
LP, as the sole general partner of AVF X Overage, may be deemed to beneficially own the AVF X Overage Record Shares. AVP X LLC,
as the sole general partner of AVP X Overage LP, may be deemed to beneficially own the AVF X Overage Record Shares. AVF
XII is the record holder of 4,131,207 shares of Common Stock (“AVF XII Record Shares”). AVP XII LP, as the sole general
partner of AVF XII LP, may be deemed to beneficially own the AVF XII Record Shares. AVP XII LLC, as the sole general partner of
AVP XII LP, may be deemed to beneficially own the AVF XII Overage Record Shares. By
virtue of their relationship as affiliated entities who have overlapping general partners and managing directors, each of the Managing
Directors and direct and indirect general partners of AVF VII and AVF VIII Overage may be deemed to share the power to direct the disposition
and vote of the AVF VII Record Shares and AVF VIII Overage Shares. By virtue of their relationship as affiliated entities who have overlapping
general partners and investment committee members, each of the Investment Committee Members and direct and indirect general partners
of AVF X, AVF X Overage and AVF XII may be deemed to share the power to direct AVF X Record Shares and AVF XII Record Shares (collectively
with AVF VII Record Shares and AVF VIII Overage Record Shares, the “Record Shares”). Burow and Gillis have a pecuniary
interest in AVP VII, and Burow has a pecuniary interest in AVP VIII LP and AVP VIII Overage LP, and while they do not have voting or
dispositive power over AVF VII Record Shares or AVF VIII Record Shares, these shares were included in the beneficial ownership reporting
for each. Burow
is also the owner of 27,617 shares of common stock of the Issuer and is the holder of vested options to purchase 16,775 shares of Common
Stock and options to purchase 2,581 shares of Common Stock that will vest within 60 days of this Schedule 13D (“Burow Options”). Each
Reporting Person disclaims beneficial ownership of the Record Shares except for the shares, if any, held of record by such Reporting
Person. CUSIP
No. 640979 100 The
percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth
on Line 13 of such Reporting Person’s cover sheet. Such percentage (other than for Burow) was calculated based on the 161,561,064
shares of Common Stock reported by the Issuer to be outstanding on November 4, 2024 in the Issuer’s Form 10-Q filed with the Securities
and Exchange Commission on November 12, 2024. For Burow, the Burow Options were included in the number of shares of Common Stock outstanding. AVF VII, AVF VIII Overage, AVF X, AVF X Overage and AVF XII are parties
to that certain Amended and Restated Investors’ Rights Agreement, dated September 22, 2022, the “Investor Rights Agreement”),
which is attached as Exhibit 10.1 to the Issuer’s Form S-1 filed on August 25, 2023. Effective as of the closing of the Issuer’s
initial public offering, the covenants relating to delivery of financial statements and inspection rights set forth in Section 3 were
terminated and rights of first offer were terminated. Pursuant to the Investor Rights Agreement, AVF VII, AVF VIII Overage, AVF X, AVF
X Overage and AVF XII have certain registration rights with respect to its Common Stock. Specifically, the Issuer has granted demand,
piggyback and Form S-3 registration rights, which will terminate upon the earlier of (i) with respect to each stockholder, such date on
which all registrable shares held by such stockholder may immediately be sold during any three-month period pursuant to Rule 144 of the
Securities Act of 1933, as amended, (ii) the occurrence of a deemed liquidation event, as defined in the Issuer’s amended and restated
certificate of incorporation, as currently in effect, and (iii) the fifth anniversary of the IPO. The foregoing description of the Investor Rights Agreement does not purport
to be complete and is qualified in its entirety by reference to the full text of such agreement filed as an exhibit to this Schedule 13D
and is incorporated herein by reference. Exhibit
1 - Agreement of Joint Filing Exhibit
2 - Agreement of Joint Filing Exhibit
3 - Agreement of Joint Filing Exhibit
4 - Agreement of Joint Filing CUSIP
No. 640979 100 Signature After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 22, 2024 ARCH Venture
Fund VII, L.P. By: ARCH Venture Partners VII,
L.P. its General
Partner By: ARCH
Venture Partners VII, LLC its General
Partner By: *
Managing
Director ARCH
Venture Partners VII, L.P. By: ARCH Venture Partners VII,
LLC its General
Partner By: *
Managing
Director ARCH VENTURE PARTNERS VII, LLC By: *
Managing
Director
* Clinton Bybee
* Keith Crandell
* Robert Nelsen * By: /s/
Mark McDonnell Mark
McDonnell as Attorney-in-Fact * This
Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24.2 to the Form 3 relating to the beneficial
ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on September
14, 2023 and incorporated herein in its entirety by reference. CUSIP
No. 640979 100 AGREEMENT
OF JOINT FILING Pursuant to Rule 13d-1(k)(1)
under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by
Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Neumora, Inc. This Agreement may be executed in any number
of counterparts, each of which shall be deemed an original. Date: November 22, 2024 ARCH Venture
Fund VII, L.P. By: ARCH Venture Partners VII,
L.P. its General
Partner By: ARCH
Venture Partners VII, LLC its General
Partner By: *
Managing
Director ARCH
Venture Partners VII, L.P. By: ARCH Venture Partners VII,
LLC its General
Partner By: *
Managing
Director ARCH VENTURE PARTNERS VII, LLC By: *
Managing
Director
* Clinton Bybee
* Keith Crandell
* Robert Nelsen * By: /s/
Mark McDonnell Mark
McDonnell as Attorney-in-Fact * This Agreement of
Joint Filing was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24.2 to the Form 3 relating to the
beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission
on September 14,2023 and incorporated herein in its entirety by reference. CUSIP
No. 640979 100
Item
5. INTEREST
OF SECURITIES OF THE ISSUER.
(a) AVF
VII is the record owner of 1,387,228 shares of Common Stock (“AVF VII Record Shares”).
AVP VII, as the sole general partner of AVF VII, may be deemed to beneficially own the AVF
VII Record Shares. AVP VII LLC, as the sole general partner of AVP VII, may be deemed
to beneficially own the AVF VII Record Shares.
13D
Page
22 of 32 Pages
(b) Regarding
the number of shares as to which such person has:
(i) sole
power to vote or to direct the vote: See line 7 of cover sheets.
(ii) shared
power to vote or to direct the vote: See line 8 of cover sheets.
(iii) sole
power to dispose or to direct the disposition: See line 9 of cover sheets.
(iv) shared
power to dispose or to direct the disposition: See line 10 of cover sheets.
(c) None of the Reporting Persons has effected any transaction in the Common
Stock during the last 60 days. This Amendment No. 2 is being filed voluntarily due to an issuance of securities by the Issuer as reported
on the Issuer’s 10-Q filed with the Securities and Exchange Commission on November 12, 2024, which caused the percentage of outstanding
Common Stock of the Issuer deemed to be beneficial owned by the Reporting Persons to reduce by one percent or more.
(d) No
other person is known to have the right to receive or the power to direct the receipt of
dividends from, or any proceeds from the sale of, shares beneficially owned by any of the
Reporting Persons.
(e) Not
applicable.
Item
6. CONTRACTS,
ARRANGEMENTS, UNDERTAKINGS OR RELATIONSHIP
S WITH RESPECT TO SECURITIES OF THE ISSUER.
Item 7. Material
to be Filed as Exhibits.
13D
Page
23 of 32 Pages
13D
Page
24 of 32 Pages
13D
Page
25 of 32 Pages
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: November 22, 2024
ARCH VENTURE FUND VIII OVERAGE, L.P.
By: ARCH Venture Partners VIII, LLC
its General Partners
By: *
Keith Crandell
Managing Director
ARCH VENTURE PARTNERS VIII, LLC
By: *
Keith Crandell
Managing Director
* By: /s/ Mark McDonnell
Mark McDonnell as
Attorney-in-Fact
* This Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24.3 to the Form 3 relating to the beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities and Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.
CUSIP No. 640979 100 |
13D | Page 26 of 32 Pages |
AGREEMENT OF JOINT FILING
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Neumora Therapeutics, Inc.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.
Date: November 22, 2024
ARCH VENTURE FUND VIII OVERAGE, L.P.
By: ARCH Venture Partners VIII, LLC
its General Partners
By: *
Keith Crandell
Managing Director
ARCH VENTURE PARTNERS VIII, LLC
By: *
Keith Crandell
Managing Director
* By: /s/ Mark McDonnell
Mark McDonnell as
Attorney-in-Fact
* This Agreement of Joint Filing was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24.3 to the Form 3 relating to the beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities and Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.
CUSIP No. 640979 100 |
13D | Page 27 of 32 Pages |
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: November 22, 2024
ARCH VENTURE FUND X, L.P.
By: ARCH Venture Partners X, L.P.
its General Partner
By: ARCH Venture Partners X, LLC
its General Partner
By: *
Robert Nelsen
Managing Director
ARCH VENTURE PARTNERS X, L.P.
By: ARCH Venture Partners X, LLC
its General Partner
By: *
Robert Nelsen
Managing Director
ARCH VENTURE PARTNERS X, LLC
By: *
Keith Crandell
Managing Director
ARCH VENTURE FUND X OVERAGE, L.P.
By: ARCH Venture Partners X Overage, L.P.
its General Partner
By: ARCH Venture Partners X, LLC
its General Partner
By: *
Robert Nelsen
Managing Director
CUSIP No. 640979 100 |
13D | Page 28 of 32 Pages |
ARCH VENTURE FUND X OVERAGE, L.P.
By: ARCH Venture Partners X Overage, L.P.
its General Partner
By: ARCH Venture Partners X, LLC
its General Partner
By: *
Robert Nelsen
Managing Director
ARCH VENTURE PARTNERS X OVERAGE, L.P.
By: ARCH Venture Partners X, LLC
its General Partner
By: *
Robert Nelsen
Managing Director
ARCH VENTURE PARTNERS X, LLC
By: *
Robert Nelsen
Managing Director
*
Keith Crandell
*
Clinton Bybee
*
Robert Nelsen
* By: /s/ Mark McDonnell
Mark McDonnell
Attorney-in-Fact
* This Schedule 13D was executed by Mark McDonnell pursuant to Powers of Attorney filed as Exhibit 24 and 24.1 to the Form 3 relating to the beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.
CUSIP No. 640979 100 |
13D | Page 29 of 32 Pages |
AGREEMENT OF JOINT FILING
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Neumora Therapeutics, Inc.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.
Date: November 22, 2024
ARCH VENTURE FUND X, L.P.
By: ARCH Venture Partners IX L.P.
its General Partner
By: ARCH Venture Partners X, LLC
its General Partner
By: *
Robert Nelsen
Managing Director
ARCH VENTURE PARTNERS X, L.P.
By: ARCH Venture Partners X, LLC
its General Partner
By: *
Robert Nelsen
Managing Director
ARCH VENTURE PARTNERS X, LLC
By: *
Robert Nelsen
Managing Director
ARCH VENTURE FUND X OVERAGE, L.P.
By: ARCH Venture Partners X Overage, L.P.
its General Partner
By: ARCH Venture Partners X, LLC
its General Partner
By: *
Robert Nelsen
Managing Director
ARCH VENTURE PARTNERS X OVERAGE, L.P.
By: ARCH Venture Partners X, LLC
its General Partner
By: *
Robert Nelsen
Managing Director
CUSIP No. 640979 100 |
13D | Page 30 of 32 Pages |
ARCH VENTURE PARTNERS X, LLC
By: *
Robert Nelsen
Managing Director
*
Keith Crandell
*
Robert Nelsen
*
Kristina Burow
*
Steven Gillis
* By: /s/ Mark McDonnell
Mark McDonnell as
Attorney-in-Fact
* This Agreement of Joint Filing was executed by Mark McDonnell pursuant to a Powers of Attorney filed as Exhibit 24 and 24.1 to the Form 3 relating to the beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.
CUSIP No. 640979 100 |
13D | Page 31 of 32 Pages |
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: November 22, 2024
ARCH VENTURE FUND XII, L.P.
By: ARCH Venture Partners XII, L.P.
its General Partner
By: ARCH Venture Partners XII, LLC
its General Partner
By: *
Keith Crandell
Managing Director
ARCH VENTURE PARTNERS XII, L.P.
By: ARCH Venture Partners XII, LLC
its General Partner
By: *
Keith Crandell
Managing Director
ARCH VENTURE PARTNERS XII, LLC
By: *
Keith Crandell
Managing Director
*
Keith Crandell
*
Robert Nelsen
*
Kristina Burow
*
Steven Gillis
* By: /s/ Mark McDonnell
Mark McDonnell
Attorney-in-Fact
* This Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24.4 to the Form 3 relating to the beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.
CUSIP No. 640979 100 |
13D | Page 32 of 32 Pages |
AGREEMENT OF JOINT FILING
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Neumora Therapeutics, Inc.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.
Date: November 22, 2024
ARCH VENTURE FUND XII, L.P.
By: ARCH Venture Partners XII L.P.
its General Partner
By: ARCH Venture Partners XII, LLC
its General Partner
By: *
Keith Crandell
Managing Director
ARCH VENTURE PARTNERS XII, L.P.
By: ARCH Venture Partners XII, LLC
its General Partner
By: *
Keith Crandell
Managing Director
ARCH VENTURE PARTNERS XII, LLC
By: *
Keith Crandell
Managing Director
ARCH VENTURE PARTNERS XII, LLC
By: *
Keith Crandell
Managing Director
*
Keith Crandell
*
Robert Nelsen
*
Kristina Burow
*
Steven Gillis
* By: /s/ Mark McDonnell
Mark McDonnell as
Attorney-in-Fact
* This Agreement of Joint Filing was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24.4 to the Form 3 relating to the beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.